. 2023 Jan 1;13(1):e2023053. doi: 10.5826/dpc.1301a53

Table 2.

Number, frequency and odds ratio (OR) for comorbid conditions of patients with atopic dermatitis between 2013 and 2021 compared to controls.

Comorbidity	ICD-10-code	Atopic dermatitis (n=2946) n (%)	OR (95% CI)	Adjusted OR ^# (95% CI)	Significance level ^##
Predominantly allergic asthma	J45.0	177 (6.0)	8.6 (7.3–10.1)	6.4 (5.5–7.5)	^***
Vasomotor and allergic rhinitis	J30	897 (30.4)	4.0 (3.7–4.4)	4.2 (3.8–4.5)	^***
Acute atopic conjunctivitis	H10.1	530 (18.0)	6.4 (5.8–7.0)	5.6 (5.1–6.2)	^***
Vitiligo	L80	21 (0.7)	2.9 (1.8–4.4)	3.5 (2.2–5.4)	^***
Alopecia areata	L63	35 (1.2)	3.8 (2.7–5.4)	3.9 (2.8–5.5)	^***
Crohn disease	K50	29 (1.0)	2.5 (1.7–3.5)	3.4 (2.4–4.9)	^***
Ulcerative colitis	K51	27 (0.9)	1.5 (1.0–2.3)	2.2 (1.5–3.2)	^***
Essential hypertension	I10	280 (9.5)	0.5 (0.4–0.5)	2.2 (1.9–2.6)	^***
Atherosclerosis	I70	12 (0.4)	0.7 (0.4–1.2)	3.5 (1.9–6.2)	^***
Cerebral infarction	I63	25 (0.8)	0.7 (0.5–1.1)	3.0 (2.0–4.6)	^***
Angina pectoris	I20	31 (1.1)	0.5 (0.3–0.7)	1.9 (1.3–2.8)	^***
Disorders of lipoprotein metabolism and other lipidemias	E78	167 (5.7)	0.4 (0.4–0.5)	1.8 (1.5–2.2)	^***
Obesity	E66	253 (8.6)	1.1 (0.9–1.2)	1.6 (1.4–1.9)	^***
Problems related to lifestyle	Z72	138 (4.7)	0.9 (0.8–1.1)	1.5 (1.3–1.8)	^***
Depressive episode	F32	364 (12.4)	1.1 (0.9–1.2)	1.4 (1.3–1.6)	^***
Other anxiety disorders	F41	502 (17.0)	1.3 (1.1–1.4)	1.5 (1.4–1.7)	^***
Obsessive-compulsive disorder	F42	42 (1.4)	2.3 (1.7–3.1)	2.0 (1.5–2.7)	^***
Non-organic sleep disorder	F51	296 (10.0)	0.9 (0.8–0.9)	1.5 (1.4–1.8)	^***
Sleep-disorders	G47	256 (8.7)	0.9 (0.9–1.1)	1.8 (1.6–2.0)	^***
Other bacterial intestinal infections	A04	31 (1.1)	1.7 (1.2–2.4)	2.4 (1.7–3.4)	^***
Erysipelas	A46	95 (3.2)	1.5 (1.2–1.8)	3.4 (2.8–4.2)	^***
Lyme disease	A69.2	140 (4.8)	1.1 (0.9–1.3)	1.7 (1.4–2.0)	^***
Herpes simplex infections	B00	145 (4.9)	3.2 (2.7–3.8)	3.3 (2.8–3.9)	^***
Viral infection of unspecified site	B34	977 (33.2)	2.1 (2.0–2.3)	1.6 (1.5–1.7)	^***
Dermatophytosis	B35	236 (8.0)	1.8 (1.5–2.0)	2.5 (2.2–2.8)	^***
Candidiasis	B37	253 (8.6)	1.7 (1.5–1.9)	2.1 (1.8–2.4)	^***
Streptococcus and staphylococcus as the cause of diseases classified to other chapters	B95	75 (2.5)	2.6 (2.1–3.3)	5.9 (4.6–7.4)	^***
Impetigo	L01	585 (19.9)	8.0 (7.3–8.8)	4.9 (4.5–5.4)	^***
Resistance to methicillin	U82.1	21 (0.7)	3.7 (2.4–5.7)	2.9 (1.9–4.5)	^***
Tobacco use	Z72.0	66 (2.2)	0.9 (0,7–1.1)	1.5 (1.2–2.0)	^***
Cerebral atherosclerosis	I67.2	1 (0.0)	3.9 (0.5–28.9)	15.3 (2.1–114.1)	^**
Chronic ischemic heart disease	I25	48 (1.6)	0.4 (0.3–0.5)	2.0 (1.5–2.8)	^**
Scabies	B86	37 (1.3)	2.2 (1.6–3.1)	1.6 (1.2–2.2)	^**
Other specified bacterial agents as the cause of diseases classified to other chapters	B96	29 (1.0)	0.7 (0.5–0.9)	1.7 (1.2–2.5)	^**
Arthritis	M05–M09	32 (1.1)	1.0 (0.7–1.5)	2.0 (1.4–2.8)	^**
Coeliac disease	K90.0	34 (1.2)	1.7 (1.2–2.5)	1.7 (1.2–2.4)	^**
Lack of physical exercise	Z72.3	12 (0.4)	1.4 (0.8–2.4)	2.1 (1.2–3.8)	^**
Hyperkinetic disorder	F90	125 (4.2)	1.8 (1.5–2.2)	1.3 (1.1–1.5)	^**
Eating disorders	F50	36 (1.2)	2.5 (1.8–3.4)	1.6 (1.1–2.2)	^**
Streptococcal sepsis	A40	3 (0.1)	1.4 (0.4–4.3)	3.9 (1.3–12.3)	^*
Meningococcal infection	A39	1 (0.0)	9.0 (1.2–67.9)	12.9 (1.6–101.7)	^*
Pneumonia due to Streptococcus pneumonia	J13	4 (0.2)	1.3 (0.5–3.6)	3.2 (1.2–8.5)	^*
Type 1 diabetes mellitus	E10	32 (1.1)	0.9 (0.6–1.3)	1.5 (1.1–2.2)	^*
Type 2 diabetes mellitus	E11	71 (2.4)	0.4 (0.3–0.5)	1.3 (1.0–1.7)	^*
Other sepsis	A41	9 (0.3)	0.6 (0.3–1.2)	2.0 (1.0–3.9)	^*
Eosinophilic esophagitis	K209A	2 (0.1)	2.9 (0.7–12.0)	3.9 (0.9–15.9)	^ns
Autism	F84.0/F84.1	40 (1.4)	1.9 (1.4–2.6)	1.2 (0.9–1.6)	^ns
Multiple sclerosis	G35	3 (0.1)	0.5 (0.2–1.5)	0.7 (0.2–2.2)	^ns
Systemic lupus erythematosus	M32	2 (0.1)	0.9 (0.2–3.5)	1.3 (0.3–5.1)	^ns
Acute myocardial infarction	I21	10 (0.3)	0.3 (0.2–0.5)	1.1 (0.6–2.1)	^ns
Subsequent myocardial infarction	I22	0 (0.0)	0.0 (0.0–0.0)	0.0 (0.0–0.0)	^ns
Certain current complications following acute myocardial infarction	I23	0 (0.0)	0.0 (0.0–0.0)	0.0 (0.0–0.0)	^ns
Other acute ischaemic heart disease	I24	0 (0.0)	0.0 (0.0–0.0)	0.0 (0.0–0.0)	^ns
Smoking	Z72.0A	43 (1.5)	0.7 (0.5–0.9)	1.3 (0.9–1.7)	^ns
Alcohol use	Z72.1	3 (0.1)	0.9 (0.3–3.0)	2.0 (0.6–6.3)	^ns
Schizophrenia	F20	2 (0.1)	0.3 (0.1–1.1)	0.5 (0.1–2.0)	^ns
Other sexually transmitted chlamydial disease	A56	60 (2.0)	1.7 (1.4–2.3)	1.2 (0.9–1.5)	^ns
Tuberculosis of skin and subcutaneous tissue	A18.4	0 (0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	^ns
Human immunodeficiency virus (HIV) disease resulting in infectious and parasitic disease	B20	0 (0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	^ns
Cytomegaloviral disease	B25	3 (0.1)	2.5 (0.8–7.8)	2.8 (0.9–8.7)	^ns
Anogenital herpesviral (herpes simplex) infection	A60	18 (0.6)	1.6 (1.0–2.5)	1.4 (0.9–2.2)	^ns
Other diseases caused by chlamydiae	A74	10 (0.4)	1.2 (0.6–2.1)	0.9 (0.5–1.8)	^ns
Gonococcal infection	A54	2 (0.1)	1.6 (0.4–6.5)	1.5 (0.4–5.9)	^ns
Viral agents as the cause of diseases classified to other chapters	B97	5 (0.2)	1.3 (0.5–3.1)	1.4 (0.6–3.3)	^ns
Tick-borne viral encephalitis	A84	0 (0.0)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	^ns
Hepatitis	B15–B18	5 (0.2)	0.4 (0.2–0.9)	0.5 (0.2–1.2)	^ns
Malignant melanoma of skin	C43	8 (0.3)	0.6 (0.3–1.1)	1.5 (0.7–3.0)	^ns
Other malignant neoplasms of skin	C44	28 (1.0)	0.4 (0.2–0.5)	1.3 (0.9–1.9)	^ns
Lymphomas	C81–C86	4 (0.1)	0.7 (0.3–1.9)	1.9 (0.7–5.2)	^ns

Odds ratio adjusted for age group and sex

^##

Significance level of adjusted odds ratio

p<0.05;

^**

p<0.01;

^***

p<0.001;

^ns

p>0.05